In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Clinical, echocardiographic and cost improvement after the onset with sacubitril-valsartan in mexican patients with heart failure.

Session Poster Session 2

Speaker Veronica Vanesa Gomez Leiva

Event : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Chronic Heart Failure: Pharmacotherapy
  • Session type : Poster Session

Authors : V V Gomez Leiva (Mexico City,MX), V E Ruiz Ruiz (Mexico City,MX), J L Fujigaki Zaldivar (Mexico City,MX), F Flores Puente (Mexico City,MX), J G Rodriguez Serrano (Mexico City,MX), L Campuzano Pineda (Mexico City,MX), E Gomez Alvarez (Mexico City,MX), J A Merino Rajme (Mexico City,MX)

Authors:
V V Gomez Leiva1 , V E Ruiz Ruiz1 , J L Fujigaki Zaldivar1 , F Flores Puente1 , J G Rodriguez Serrano1 , L Campuzano Pineda1 , E Gomez Alvarez1 , J A Merino Rajme1 , 1National Medical Center 20 de Noviembre - Mexico City - Mexico ,

On behalf: Gómez Leiva, Veronica V

Citation:

INTRODUCTION. In Mexico, heart failure (HF) has a prevalence of 1.6 million persons and annual incidence of 600,000 new cases. 

Sacubitril/Valsartan (S/V) has proved to be superior than conventional therapy decreasing the number of readmissions in the emergency room, days in the intensive care unit, total hospitalizations days, improve in quality of life and survival, echocardiography has shown improvement in the left ventricular ejection fraction (LVEF) and reverse remodeling achieved. 

PURPOSE. Compare the echocardiographic parameters, quality of life, institutional costs, tolerance and side effects in patients with heart failure with reduced ejection fraction before and after 3 months therapy with S/V. 

METHODS. Patients diagnosed with HF, LVEF =35%, persistence of symptoms and treated with conventional therapy were recruited to initiate S/V therapy. After written consent was obtain, echocardiographic parameters (LVEF, diastolic diameter, systolic diameter, diastolic function and pulmonary artery systolic pressure), quality of life: 6-minute walk test (6-MWT) and Kansas City cardiomyopathy questionnaire (KCCQ) and institutional cost were measured; follow-up was made at three months, with the same parameters. 

Data analysis was made with SPSS statistical program (v 24.0). Data is presented as means and standard deviations, frequencies and percentages. The distribution of variables was determined with the Shapiro-Wilk test; Wilcoxon and Friedman test were used. Statistically significant was taken at p <0.05. 

RESULTS. 25 patients were enrolled. Baseline characteristics: mean age 54 years (± 13.7), women 32%, non-ischemic 52%, 52% without pacemaker, 12% with implantable cardioverter defibrillator (ICD), 12% with cardiac resynchronization therapy (CRT) and 24% with ICD-CRT. 68% were non responders (59% ischemic), 20% responders (60% non-ischemic) and 12% super responders (all non-ischemic). 

Echocardiographic parameters exhibited the reverse remodeling achieved, improvement in the LVEF (26.1% ± 7.3 to 29.9 ± 8.5, p 0.02), diastolic diameter (61.2±9.5 to 60.4±7.2, p 0.57), systolic diameter LV (50.8±11.8 to 50.3±10.8, p 0.80), pulmonary artery systolic pressure (32.4±15.4 to 32.6±17.1, p 0.64), diastolic function (grade II to grade I or absence, p 0.23). Improvement in the 6-MWT (430.6±152.6 to 472.3±91, p 0.16), KCCQ (41.7±14.2 to 56.7±7 p 0.005). 

Hospitalized (4.7±10.2 to 0.2±1, p 0.02) and disabilities (8.8±22.9 to 0.1±0.8 p 0.08) days decreased, dose tolerance (100mg bid) was 80% with a decrease in side effects. Institutional cost for three months with triple therapy was US $54,547.74 and for S/V was US $ 9,659.45. 

CONCLUSION. The therapy with S/V for the treatment of patients with HF and LVEF =35% with persistence of symptoms shows an improvement in the quality of life by KQ, reverse left ventricular remodeling, further institutional saving was US $ 44,888.29 this could be related with a decrease in hospitalizations days.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are